Search Results - "Klostergaard, Jim"

Refine Results
  1. 1

    Combinatorial Selection of DNA Thioaptamers Targeted to the HA Binding Domain of Human CD44 by Somasunderam, Anoma, Thiviyanathan, Varatharasa, Tanaka, Takemi, Li, Xin, Neerathilingam, Muniasamy, Lokesh, Ganesh Lakshmana Rao, Mann, Aman, Peng, Yang, Ferrari, Mauro, Klostergaard, Jim, Gorenstein, David G

    Published in Biochemistry (Easton) (26-10-2010)
    “…CD44, the primary receptor for hyaluronic acid, plays an important role in tumor growth and metastasis. CD44−hyaluronic acid interactions can be exploited for…”
    Get full text
    Journal Article
  2. 2

    Hyaluronic Acid- Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts by Auzenne, Edmond, Ghosh, Sukhen C., Khodadadian, Mojgan, Rivera, Belinda, Farquhar, David, Price, Roger E., Ravoori, Murali, Kundra, Vikas, Freedman, Ralph S., Klostergaard, Jim

    Published in Neoplasia (New York, N.Y.) (01-06-2007)
    “…Numerous human tumor types, including ovarian cancer, display a significant expression of the CD44 family of cell surface proteoglycans. To develop…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms by Yan, Hong, Chen, Xin, Zhang, Qiuping, Qin, Jichao, Li, Hangwen, Liu, Can, Calhoun-Davis, Tammy, Coletta, Luis Della, Klostergaard, Jim, Fokt, Izabela, Skora, Stanislaw, Priebe, Waldemar, Bi, Yongyi, Tang, Dean G

    Published in PloS one (15-09-2011)
    “…Cancer stem cells (CSCs) possess high tumor-initiating capacity and have been reported to be resistant to therapeutics. Vice versa, therapy-resistant cancer…”
    Get full text
    Journal Article
  5. 5

    Antitumor Activity of Hydrophilic Paclitaxel Copolymer Prodrug Using Locoregional Delivery in Human Orthotopic Non–Small Cell Lung Cancer Xenograft Models by Zou, Yiyu, Fu, Hao, Ghosh, Sukhen, Farquhar, David, Klostergaard, Jim

    Published in Clinical cancer research (01-11-2004)
    “…Paclitaxel (Taxol) has demonstrated clinical activity in non–small-cell lung cancer (NSCLC), but its use has not led to marked improvements in survival. This…”
    Get full text
    Journal Article
  6. 6

    Superior Therapeutic Profile of Poly-l-Glutamic Acid-Paclitaxel Copolymer Compared with Taxol in Xenogeneic Compartmental Models of Human Ovarian Carcinoma by AUZENNE, Edmond, DONATO, Nicholas J, CHUN LI, LEROUX, Elena, PRICE, Roger E, FARQUHAR, David, KLOSTERGAARD, Jim

    Published in Clinical cancer research (01-02-2002)
    “…Previous preclinical studies with ectopic tumor models have demonstrated remarkable improvements in the therapeutic profile of paclitaxel, formulated as a…”
    Get full text
    Journal Article
  7. 7

    BRAF Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues by Sahin, Ibrahim Halil, Klostergaard, Jim

    Published in JCO oncology practice (01-12-2021)
    “…mutations in colorectal cancer have been studied over the past several decades. V600E mutation, a class I mutation, is the most common oncogenic alteration in…”
    Get more information
    Journal Article
  8. 8

    Precision medicine for metastatic colorectal cancer: an evolving era by Guler, Irem, Askan, Gokce, Klostergaard, Jim, Sahin, Ibrahim Halil

    “…: Metastatic colorectal cancer (CRC) remains a dilemma for cancer researchers with an increasing incidence in the younger patient population. Until the last…”
    Get more information
    Journal Article
  9. 9

    Transmembrane TNF (pro-TNF) is palmitoylated by Utsumi, Toshihiko, Takeshige, Tomonori, Tanaka, Kenji, Takami, Kenji, Kira, Yukimi, Klostergaard, Jim, Ishisaka, Rumi

    Published in FEBS letters (29-06-2001)
    “…Human transmembrane tumor necrosis factor (pro-TNF) was examined for protein acylation. The cDNA encoding pro-TNF was expressed in both COS-1 cells and Sf9…”
    Get full text
    Journal Article
  10. 10

    Magnetic nanovectors for drug delivery by Klostergaard, Jim, Seeney, Charles E

    Published in Nanomedicine (01-09-2012)
    “…Abstract Nanotechnology holds the promise of novel and more effective treatments for vexing human health issues. Among these are the use of nanoparticle…”
    Get full text
    Journal Article
  11. 11

    CD44: a validated target for improved delivery of cancer therapeutics by Ghosh, Sukhen C, Neslihan Alpay, Sultan, Klostergaard, Jim

    Published in Expert opinion on therapeutic targets (01-07-2012)
    “…Advances in cancer therapeutics, namely more effective and less toxic treatments, will occur with targeting strategies that enhance the tumor biodistribution…”
    Get more information
    Journal Article
  12. 12

    CD44 as a drug delivery target in human cancers: where are we now? by Sahin, Ibrahim H, Klostergaard, Jim

    Published in Expert opinion on therapeutic targets (02-12-2015)
    “…In the treatment of cancers, the dual goals of drug targeting are to deliver therapeutic agents more selectively to tumor tissue and to minimize exposure of…”
    Get more information
    Journal Article
  13. 13

    Magnetic nanovectors for drug delivery by Klostergaard, Jim, Seeney, Charles E

    Published in Maturitas (01-09-2012)
    “…Abstract Nanotechnology holds the promise of novel and more effective treatments for vexing human health issues. Among these are the use of nanoparticle…”
    Get full text
    Journal Article
  14. 14

    Targeting SH2 domains in breast cancer by Morlacchi, Pietro, Robertson, Fredika M, Klostergaard, Jim, McMurray, John S

    Published in Future medicinal chemistry (01-01-2014)
    “…Breast cancer is among the most commonly diagnosed cancer types in women worldwide and is the second leading cause of cancer-related disease in the USA. SH2…”
    Get more information
    Journal Article
  15. 15

    TRIB2 contributes to cisplatin resistance in small cell lung cancer by Liang, Yuanxin, Yu, Dong, Perez-Soler, Roman, Klostergaard, Jim, Zou, Yiyu

    Published in Oncotarget (12-12-2017)
    “…Small cell lung cancer (SCLC) is the most aggressive lung-cancer subtype and so far, no favorable therapeutic strategy has been established for chemo-resistant…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Human pro-tumor necrosis factor: molecular determinants of membrane translocation, sorting, and maturation by Utsumi, Toshihiko, Akimaru, Kunihiro, Kawabata, Zenichiro, Levitan, Alla, Tokunaga, Tetsuhiro, Tang, Ping, Ide, Akio, Hung, Mien-Chie, Klostergaard, Jim

    Published in Molecular and Cellular Biology (01-11-1995)
    “…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
    Get full text
    Journal Article
  18. 18

    A Part of the Transmembrane Domain of pro-TNF Can Function as a Cleavable Signal Sequence That Generates a Biologically Active Secretory Form of TNF by Ishisaka, Rumi, Sato, Noriyuki, Tanaka, Kenji, Takeshige, Tomonori, Iwata, Hiroyuki, Klostergaard, Jim, Utsumi, Toshihiko

    Published in Journal of biochemistry (Tokyo) (01-08-1999)
    “…To determine the minimum requirement in the 76-residue leader sequence of pro-tumor necrosis factor (TNF) for membrane translocation across the endoplasmic…”
    Get full text
    Journal Article
  19. 19

    Hyaluronic acid–paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism by Galer, Chad E, Sano, Daisuke, Ghosh, Sukhen C, Hah, Jeong H, Auzenne, Edmund, Hamir, Amirali N, Myers, Jeffrey N, Klostergaard, Jim

    Published in Oral oncology (01-11-2011)
    “…Summary Chemotherapeutic regimens incorporating taxanes significantly improve outcomes for patients with squamous cell carcinomas of the head and neck (SCCHN)…”
    Get full text
    Journal Article
  20. 20

    Magnetically vectored platforms for the targeted delivery of therapeutics to tumors: history and current status by Seeney, Charles, Ojwang, Joshua O, Weiss, Ronald D, Klostergaard, Jim

    Published in Nanomedicine (London, England) (01-02-2012)
    “…Superparamagnetic iron oxide nanoparticles (SPIONs) are being developed as vehicles for the selective targeting of therapeutics and bioactive compounds…”
    Get more information
    Journal Article